Vicore Pharma Holding AB

Vicore Pharma is a Swedish clinical biopharmaceutical company headquartered in Stockholm, founded in 2000, specialized in respiratory and fibrotic diseases. Its lead candidate buloxibutid is the first-in-class oral angiotensin II type 2 (AT2) receptor agonist, with FDA Orphan Drug and Fast Track designations, currently in the global Phase 2b ASPIRE trial for idiopathic pulmonary fibrosis (IPF). Positive Phase 2a results (AIR trial). Also commercializes Almee™, a digital therapy for psychological symptom burden in IPF. Listed on Nasdaq Stockholm.